CA2697451A1 - Derives d'indole tetracycliques et procedes pour les utiliser - Google Patents

Derives d'indole tetracycliques et procedes pour les utiliser Download PDF

Info

Publication number
CA2697451A1
CA2697451A1 CA2697451A CA2697451A CA2697451A1 CA 2697451 A1 CA2697451 A1 CA 2697451A1 CA 2697451 A CA2697451 A CA 2697451A CA 2697451 A CA2697451 A CA 2697451A CA 2697451 A1 CA2697451 A1 CA 2697451A1
Authority
CA
Canada
Prior art keywords
alkyl
cycloalkyl
compound
heteroaryl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2697451A
Other languages
English (en)
Inventor
Frank Bennett
Qingbei Zeng
Srikanth Venkatraman
Mousumi Sannigrahi
Kevin X. Chen
Gopinadhan N. Anilkumar
Stuart B. Rosenblum
Joseph A. Kozlowski
F. George Njoroge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2697451A1 publication Critical patent/CA2697451A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2697451A 2007-08-29 2008-08-27 Derives d'indole tetracycliques et procedes pour les utiliser Abandoned CA2697451A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96868407P 2007-08-29 2007-08-29
US60/968,684 2007-08-29
PCT/US2008/010147 WO2009032123A2 (fr) 2007-08-29 2008-08-27 Dérivés d'indole tétracycliques et procédés pour les utiliser

Publications (1)

Publication Number Publication Date
CA2697451A1 true CA2697451A1 (fr) 2009-03-12

Family

ID=40319417

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2697451A Abandoned CA2697451A1 (fr) 2007-08-29 2008-08-27 Derives d'indole tetracycliques et procedes pour les utiliser

Country Status (11)

Country Link
EP (1) EP2197884A2 (fr)
JP (1) JP5179585B2 (fr)
KR (1) KR20100061819A (fr)
CN (1) CN101842376A (fr)
AR (1) AR068109A1 (fr)
AU (1) AU2008295483B2 (fr)
CA (1) CA2697451A1 (fr)
MX (1) MX2010002316A (fr)
TW (1) TW200918536A (fr)
WO (1) WO2009032123A2 (fr)
ZA (1) ZA201001391B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5501251B2 (ja) 2008-01-11 2014-05-21 アルバニー モレキュラー リサーチ， インコーポレイテッド Ｍｃｈ拮抗薬としての（１−アジノン）置換ピリドインドール類
JP5580814B2 (ja) * 2008-06-13 2014-08-27 メルク・シャープ・アンド・ドーム・コーポレーション ３環式インドール誘導体およびその使用方法
ES2383273T3 (es) 2008-07-23 2012-06-19 F. Hoffmann-La Roche Ag Compuestos heterocíclicos antivíricos
JP2012503620A (ja) 2008-09-26 2012-02-09 エフ．ホフマン−ラ ロシュ アーゲー Ｈｃｖを処置するためのピリンまたはピラジン誘導体
AU2010240888A1 (en) 2009-04-25 2011-11-17 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
AU2010253791A1 (en) 2009-05-29 2011-11-24 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
TWI428332B (zh) 2009-06-09 2014-03-01 Hoffmann La Roche 雜環抗病毒化合物
CA2762675A1 (fr) 2009-06-24 2010-12-29 F. Hoffmann-La Roche Ag Compose antiviral heterocyclique
EP2448585B1 (fr) 2009-07-01 2014-01-01 Albany Molecular Research, Inc. Antagonistes de mch-1 d azépino[b]indole et pyrido-pyrrolo-azépine azinone-substitué, procédés de préparation, et utilisation de ceux-ci
WO2011003007A1 (fr) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Antagonistes de mch-1 d’azabicycloalcane-indole et d’azabicycloalcane-pyrrolo-pyridine, procédés de préparation, et utilisation de ceux-ci
WO2011003012A1 (fr) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Antagonistes de mch-1 azapolycycles substitués par azinone, leurs procédés de fabrication et leur utilisation
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
JP2013505218A (ja) 2009-09-21 2013-02-14 エフ．ホフマン−ラ ロシュ アーゲー 複素環式抗ウイルス化合物
AU2010324871A1 (en) 2009-11-25 2012-06-14 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
AU2010341537A1 (en) 2009-12-22 2012-08-09 Merck Sharp & Dohme Corp. Fused Tricyclic Compounds and methods of use thereof for the treatment of viral diseases
SG183526A1 (en) 2010-03-09 2012-09-27 Merck Sharp & Dohme Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
EP2566697B1 (fr) 2010-05-02 2020-12-09 Xjet Ltd. Système d'impression pourvu de dispositifs de purge automatique, de prévention de dépôt et d'élimination d'émanations
JP2013541499A (ja) 2010-07-26 2013-11-14 メルク・シャープ・エンド・ドーム・コーポレイション 置換されたビフェニレン化合物およびウイルス性疾患の治療のためのその使用方法
EP2621932A4 (fr) * 2010-09-29 2014-03-26 Merck Sharp & Dohme Composés hétérocycliques tétracycliques pour le traitement d'une infection par le virus de l'hépatite c
AU2011314168A1 (en) 2010-09-29 2013-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
BR112013026345A2 (pt) 2011-04-13 2019-04-24 Merck Sharp & Dohe Corp. composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
WO2013033899A1 (fr) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Composés benzofuranes substitués et leur procédés d'utilisation pour le traitement de maladies virales
WO2013033901A1 (fr) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Dérivés benzofuranes substitués par un hétérocycle et leurs procédés d'utilisation pour le traitement de maladies virales
WO2013033900A1 (fr) * 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de maladies virales
EP2755981A4 (fr) 2011-09-14 2015-03-25 Merck Sharp & Dohme Composés hétérocycliques contenant un silyle et méthodes d'utilisation desdits composés pour traiter les maladies virales
AR092959A1 (es) 2012-10-17 2015-05-06 Merck Sharp & Dohme Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
US9242988B2 (en) 2012-10-17 2016-01-26 Merck Sharp & Dohme Corp. 2′-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP2909210A4 (fr) 2012-10-17 2016-04-06 Merck Sharp & Dohme Dérivés nucléosides substitués 2'-disubstitués et leurs procédés d'utilisation pour le traitement de maladies virales
RU2015123641A (ru) 2012-11-19 2017-01-10 Мерк Шарп И Доум Корп. 2-алкинилзамещенные производные нуклеозидов, предназначенные для лечения вирусных заболеваний
US9765107B2 (en) 2013-06-18 2017-09-19 Merck Sharp & Dohme Corp. Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2014205592A1 (fr) 2013-06-24 2014-12-31 Merck Sharp & Dohme Corp. Composés hétérocycliques et leurs procédés d'utilisation pour le traitement de l'hépatite c
WO2014205593A1 (fr) 2013-06-24 2014-12-31 Merck Sharp & Dohme Corp. Composés de benzofurane substitués et leurs méthodes d'utilisation pour le traitement de maladies virales
WO2015065817A1 (fr) 2013-10-30 2015-05-07 Merck Sharp & Dohme Corp. Pseudopolymorphes d'un inhibiteur de la protéine ns5a du vhc et leurs utilisations
US10899788B2 (en) 2016-06-20 2021-01-26 Merck Sharp & Dohme Corp. Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases
CN112898312B (zh) * 2021-01-29 2021-11-12 湖南南新制药股份有限公司 一种稠合多环吡啶酮衍生物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
JP2008514611A (ja) * 2004-09-23 2008-05-08 ワイス Ｃ型肝炎ウイルスによる感染を処置するためのカルバゾールおよびシクロペンタインドールの誘導体
GB0518390D0 (en) * 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2623026A1 (fr) * 2005-09-23 2007-04-05 Schering Corporation Antagonistes du mglur1 tetracycliques fusionnes utilises en tant qu'agents therapeutiques

Also Published As

Publication number Publication date
EP2197884A2 (fr) 2010-06-23
AU2008295483A1 (en) 2009-03-12
JP5179585B2 (ja) 2013-04-10
JP2010537980A (ja) 2010-12-09
ZA201001391B (en) 2010-11-24
KR20100061819A (ko) 2010-06-09
TW200918536A (en) 2009-05-01
AR068109A1 (es) 2009-11-04
AU2008295483B2 (en) 2013-11-21
WO2009032123A2 (fr) 2009-03-12
CN101842376A (zh) 2010-09-22
WO2009032123A3 (fr) 2009-06-11
MX2010002316A (es) 2010-03-22

Similar Documents

Publication Publication Date Title
AU2008295483B2 (en) Tetracyclic indole derivatives and their use for treating or preventing viral infections
AU2008295484B2 (en) Substituted indole derivatives and methods of use thereof
AU2008295485B2 (en) 2,3-substituted azaindole derivatives for treating viral infections
AU2008295476B2 (en) 2, 3-Substituted Indole Derivatives for treating viral infections
EP2081922B1 (fr) Dérivés indoliques condensés en 5,6 à un cycle et leur utilisation
AU2007339386B8 (en) 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
EP2064180B1 (fr) Dérivés indoliques condensés en positions 4 et 5 utilisés pour le traitement ou la prévention des infections par le vhc et autre infections virales associées
US20110104109A1 (en) Tetracyclic indole derivatives and their use for treating or preventing viral infections

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130823

FZDE Dead

Effective date: 20160108